Bulletin from Artimplant AB's Annual Meeting of Stockholders 2012
Adoption of financial statements, disposition of result and discharge of directors and officers
The financial statements of 2011 for the group and the parent company were adopted. The Annual Meeting decided that the Parent Company’s retained loss of SEK 9,235,880 will be carried forward and that no dividend will be paid. The directors and officers of the Company were granted discharge.
Election of Board members and auditor
Anders Cedronius was reelected as chairman of the Board and John Arnold, Rickard Brånemark, Lars Peterson, Håkan Johansson were reelected as ordinary Board member and Anders Strid was elected as new ordinary Board members.
Ernst & Young AB, with Björn Grundvall as responsible auditor, was elected for a four year period at the AGM 2010 and remains until AGM 2014.
Adoption of fees
The Annual Meeting decided that the fee to the Board of Directors shall be the same as previous year,
SEK 240,000 (240,000) to the chairman and SEK 120,000 (120,000) to ordinary Board members. It was also decided that the fee to the chairman of the audit committee shall be SEK 20,000 (20,000) and the fee to the other members shall be SEK 10,000 (10,000). It was decided that no remuneration committee is necessary. The audit fee will the upcoming year be in accordance with the existing agreement for audit services, SEK 200,000 per year.
The Annual Meeting decided that the election committee before the Annual Meeting 2013, shall be appointed by representatives from the three largest stockholders, according to voting power, as of September 30, 2012.
Principles for remuneration to senior management
The Annual Meeting adopted the principles for remuneration to senior management as suggested by the Board of Directors.
The proposed incentive program was adopted by the Annual Meeting.
All above decisions were taken unanimously.
For additional information, please contact:
Kjell Thörnbring, CEO, phone +46 (0)703 11 90 25,
Further information is available at www.artimplant.com. To subscribe to future press releases please go to www.artimplant.com/investors-media/subscribe-to-press-releases.html
Artimplant is a biomaterials company focused on solutions to problems in orthopedic and oral surgery. We restore health through the development, production and marketing of degradable implants that regenerate body functions and improve quality of life. Our products, made from Artelon®, meet unmet clinical needs and are marketed in a growing number of therapy areas. Artimplant produces implants for treatment of osteoarthritis in hands and feet, for shoulder and other soft tissue injuries as well as oral surgery and veterinary medical applications.
Artimplant is a public company listed on the NASDAQ OMX Stockholm Exchange in the Small Cap segment and in the healthcare sector.
This press release contains forward-looking statements as defined in the U.S. Private Securities Litigation Reform Act of 1995. Readers are cautioned not to place undue reliance on these forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of risks and uncertainties impacting the Company's business including increased competition; the ability of the Company to expand its operations and to attract and retain qualified professionals; technological obsolescence; general economic conditions; and other risks detailed from time to time in the Company's filings.
This is information which Artimplant shall make public pursuant to the Swedish Financial Instruments Act and the Swedish Securities Exchange and Clearing Operations Act and/or stock market agreements. Information was made available for publication on May 4, 2012 at 8:55 AM (CET).